The Covid-19 pandemic, which began four years ago, has had a devastating impact on the world, claiming the lives of millions of people. One of the key strategies in controlling the spread of the virus was the development of effective vaccines, which have played a crucial role in saving lives.
Despite their success in controlling the spread of the virus, pharmaceutical companies such as Pfizer, BioNTech and Moderna have not seen the financial gains they were expecting. While revenues from vaccine sales were substantial, investors have not viewed them as sustainable sources of income.
For example, Pfizer’s sales of its vaccine with BioNTech exceeded $80 billion, with millions of doses administered in the U.S. alone. However, Pfizer’s stock price has fallen by 32% over the past five years, indicating that investors are not convinced of its long-term profitability. In contrast, AstraZeneca’s share price has risen by 64% since it stopped including vaccine sales in its financial reports last April. Similarly, Merck saw a 56% increase in its stock price despite unsuccessful vaccine efforts.
Despite significant sales and their role in mitigating the pandemic, investors have not viewed these revenues as indicators of future success for pharmaceutical companies. The dynamic nature of the market and uncertainty surrounding long-term demand for vaccines have led to mixed reactions from investors in
